Detalhe da pesquisa
1.
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Br J Cancer
; 130(8): 1377-1387, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38396173
2.
Metabolism-driven in vitro/in vivo disconnect of an oral ERÉ VHL-PROTAC.
Commun Biol
; 7(1): 563, 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740899
3.
Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit.
ACS Chem Biol
; 18(2): 296-303, 2023 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36602435
4.
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology.
J Med Chem
; 66(1): 384-397, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36525250
5.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 64, 2023 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543694
6.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 76, 2023 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726304
7.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 69, 2023 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37596288
8.
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.
Oncotarget
; 8(41): 69219-69236, 2017 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29050199